



# Manuela Curescu

Data nașterii: 30/06/1954 | **Cetățenie:** română | **Gen:** Feminin | (+40) 256205190 |

[manuela.curescu@gmail.com](mailto:manuela.curescu@gmail.com)

## COMPETENȚE LINGVISTICE

Limbă(i) maternă(e): **ROMÂNĂ**

Altă limbă (Alte limbi):

	COMPREHENSIUNE		VORBIT		SCRIS
	Comprehensiune orală	Citit	Exprimare scrisă	Conversație	
<b>ENGLEZĂ</b>	B2	B2			B1

*Niveluri: A1 și A2 Utilizator de bază B1 și B2 Utilizator independent C1 și C2 Utilizator experimentat*

## COMPETENȚE DIGITALE

Microsoft Office (Excel PowerPoint Word) - nivel intermediar | Microsoft office word | Microsoft Word  
Microsoft Excel Power Point

## EXPERIENȚA PROFESIONALĂ

01/09/1978 – 06/1982 – Timisoara , România

**SEF PROMOTIE – UNIVERSITATEA DE MEDICINA SI FARMACIE VICTOR BABES TIMISOARA**

1982 – 1984

**MEDIC STAGIAR**

1984 – 1988

**MEDIC REZIDENT BOLI INFECTIOASE – SPITALUL CLINIC DE BOLI INFECTIOASE SI PNEUMOPTIZIOLOGIE VICTOR BABES**

1988 – 1993 – Timisoara

**MEDIC SPECIALIST BOLI INFECTIOASE – SPITALUL CLINIC DE BOLI INFECTIOASE SI PNEUMOPTIZIOLOGIE VICTOR BABES**

1993 – ÎN CURS

**MEDIC PRIMAR BOLI INFECTIOASE – SPITALUL CLINIC DE BOLI INFECTIOASE SI PNEUMOPTIZIOLOGIE VICTOR BABES**

1984 – 1996

1996 – 2001 – Timisoara

**SEF LUCRARI – UNIVERSITATEA DE MEDICINA SI FARMACIE VICTOR BABES TIMISOARA**

---

2001 – ÎN CURS – Timisoara

**CONFERENTIAR – SPITALUL CLINIC DE BOLI INFECTIOASE SI PNEUMOTIZIOLOGIE VICTOR BABES**

---

## ● **PUBLICAȚII**

---

**1. 1993: Grantul Academiei Romane : “Programare prospectiva pe calculator in limbaj C++ si Sistem Expert in patogenia si terapia bolilor infectioase”. Director de grant: prof. Dr. Mihail Dragomirescu. Membru in echipa de cercetare**

---

**2. 1999 – 2001: Studiul SUCCES I si II in Romania : Terapia bolnavilor cu infectie HIV-SIDA (coordonator studiu). Sponsor MSD**

---

**3. 2003-2005: Phase II Randomised, Multicenter, Multinational Open- label study to evaluate the Efficacy and safety of Pegylated Interferon Alpha + Ribavirin + Histamine Dihydrochloride Injection (HDC) in Patients with Chronic Hepatitis C Virus Infection. M0406 Phase 2 trial. Subinvestigator**

---

**4. 2004: Efficacy and Safety of XM 02 compared to Filgrastim in patients with breast cancer receiving chemotherapy. A multinational, multicentre, randomized, controlled study. Phase III Study. BioGenerix Study No. XM02- 02- INT Subinvestigator**

---

**5. 2004: A phase III randomized, placebo-controlled study of Sorafenib in patients with advanced hepatocellular carcinoma. Protocol number BAY 43-9006. Subinvestigator**

---

**6. 2004: Safety and Efficacy of XM02 in patients with small cell or non small cell lung cancer receiving platinum - based chemotherapy. Multinational, multicentre, randomized, controlled study. Phase III Study. BioGenerix Study No. XM02- 03- INT. Subinvestigator**

---

**7. 2004: Two arm , randomized (2:1) open – label phase II/III study in EpCAM positive cancer patients with symptomatic malignant ascites, using paracentesis plus tri- functional antibody removab®(anti- EpCAM x anti-CD3), versus paracentesis alone. Studiu clinic Multicentric, multinational, randomizat. IP- REM- AC-01. Subinvestigator**

---

**12. 2006: Evaluarea raspunsului virusologic precoce ( RVP) si a raspunsului virusologic sustinut (RVS) la pacientii cu hepatita cronica cu virus c si transaminaze normale, tratati conform practicii medicale curente cu Pegasys ( peginterferon alfa 2a) si Copegus ( Ribavirina). Sponsor Roche Romania. Investigator principal**  
**2003: Phase II Randomised, Multicenter, Multinational Open- label study to evaluate the Efficacy and safety of Pegylated Interferon Alpha + Ribavirin + Histamine Dihydrochloride**

---

**13. 2006: Studiu epidemiologic, national, multicentric, de evaluare a genotipurilor virusului hepatitei B la pacientii din Romania precum si de evaluare non - interventionala a compliantei la tratamentul standard cu Peginterferon la pacientii naivi vs pacienti pre-tratati cu lamivudina/Interferon conventional in functie de genotipul VHB care au inceput tratamentul standard cu Peginterferon dupa 1 Noiembrie 2006 . Studiul ML 20970 . Sponsor Roche Romania; Study coordinator**

---

**14. 2007: Studiul multicentric international Prophesys : Prospective observational study on predictors of early on-treatment response and sustained virological response in a cohort of treatment naïve HCV-infected patients treated with pegylated interferons. Protocol Number: MV21012, 2007. F. HOFFMANN-LA ROCHE LTD/INC/AG/ROCHE GLOBAL BUSINESS. Investigator principal**

---

**16. 2004: A phase III randomized, placebo-controlled study of Sorafenib in patients with advanced hepatocellular carcinoma. Protocol number BAY 43-9006, Sharp study. Subinvestigator**

---

**25. 2008- 2010: HERO I . Observational, retrospective cohort study to evaluate pre-treatment and on treatment predictors of response to peginterferon alfa and ribavirin therapy in chronic viral Hepatitis C in real life medical practice in Romania, protocol ML 21909.**

---

**21. 2006: Evaluarea raspunsului virusologic precoce ( RVP) si a raspunsului virusologic sustinut (RVS) la pacientii cu hepatita cronica cu virus c si transaminaze normale, tratati conform practicii medicale curente cu Pegasys ( peginterferon alfa 2a) si Copegus ( Ribavirina). Principal Investigator**

---

**22. 2006: Studiu epidemiologic, national, multicentric, de evaluare a genotipurilor virusului hepatitei B la pacientii din Romania precum si de evaluare non - interventionala a compliantei la tratamentul standard cu Peginterferon la pacientii naivi vs pacienti pe-tratati cu lamivudina/Interferon conventional in functie de genotipul VHB care au inceput tratamentul standard cu Peginterferon dupa 1 Noiembrie 2006. Principal Investigator**

---

**26. 2009-2010: HERO II. Observational, retrospective cohort study to evaluate pre-treatment and on treatment predictors of response to peginterferon alfa and ribavirin therapy in chronic viral Hepatitis C in real life medical practice in Romania, protocol ML 21914.**

---

**31. 2010-2012: Randomized, Double-Blind Study of Nitazoxanide plus Peginterferon Alfa-2a and Ribavirin or Nitazoxanide plus Peginterferon Alfa-2a without Ribavirin Compared to Placebo plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients with Chronic Hepatitis C genotype 1. RM06-3001. Subinvestigator**

---

**41. 2013- 2014: M13-774; A randomized, Open- Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with Pegylated Interferon alfa-2a and Ribavirin in Treatment-Naïve Adults with Chronic Hepatitis C Genotype 1 Virus Infection. Phase (Malachite I). Phase 3b. Principal Investigator**

---